Want to see AU:PKY full AI Analyst Report?
Top Page
Opyl Ltd.
(Sydney:PKY)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.02
â–¼(-42.50% Downside)
Action:Reiterated
Date:10/02/26
The score is held down primarily by weak financial performance (persistent losses, deeply negative margins, and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD and very oversold momentum). A stronger latest balance sheet (large equity base and zero debt) provides some cushioning, but valuation is not supportive given the negative P/E and lack of dividend data.
Positive Factors
Debt-free balance sheet
The latest balance sheet shows substantial equity and no reported debt, reducing leverage pressure and preserving flexibility to fund operations. This cushion can support continued development of the company’s platforms while limiting interest burdens during a period of weak profitability.
Negative Factors
Persistent unprofitability
Repeated annual losses and a deeply negative latest net margin show that the business has not yet converted its operations into sustainable earnings. Continued unprofitability limits internally generated funding, weakens returns on capital, and leaves performance highly sensitive to revenue recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The latest balance sheet shows substantial equity and no reported debt, reducing leverage pressure and preserving flexibility to fund operations. This cushion can support continued development of the company’s platforms while limiting interest burdens during a period of weak profitability.
Read all positive factors
Opyl Ltd. (PKY) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$31.09M
Dividend YieldN/A
Average Volume (3M)2.21M
Price to Earnings (P/E)―
Beta (1Y)2.45
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,351,573,000
10 Day Avg. Volume1,191,868
30 Day Avg. Volume2,207,860
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.74
Price to Sales (P/S)621.50
P/FCF Ratio-28.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Opyl Ltd. Business Overview & Revenue Model
Company Description
Pathkey.AI Ltd is an Australian digital health firm that harnesses artificial intelligence (AI) to advance clinical trials and improve the predictability of patient outcomes, particularly within Australia. The company presents a suite of AI-driven...
Opyl Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 47.63K | 27.78K | 397.64K | 397.64K | 617.91K |
| Gross Profit | -2.81M | -778.89K | -1.40M | -1.86M | -930.36K |
| EBITDA | -3.85M | -1.66M | -2.68M | -1.70M | -2.27M |
| Net Income | -3.65M | -1.45M | -3.13M | -3.13M | -1.73M |
Balance Sheet | |||||
| Total Assets | 40.31M | 513.28K | 411.60K | 411.60K | 709.58K |
| Cash, Cash Equivalents and Short-Term Investments | 3.41M | 436.90K | 374.64K | 452.88K | 786.33K |
| Total Debt | 0.00 | 411.73K | 0.00 | 300.00K | 300.00K |
| Total Liabilities | 470.51K | 781.65K | 501.76K | 501.76K | 712.21K |
| Stockholders Equity | 39.84M | -268.37K | -90.16K | -403.59K | 267.01K |
Cash Flow | |||||
| Free Cash Flow | -1.05M | -1.29M | -2.07M | -1.37M | -1.53M |
| Operating Cash Flow | -1.05M | -1.28M | -2.06M | -1.36M | -1.52M |
| Investing Cash Flow | -168.42K | -334.02K | -17.71K | -2.22K | -2.22K |
| Financing Cash Flow | 4.52M | 1.35M | 2.00M | 1.03M | 1.03M |
Opyl Ltd. Technical Analysis
Negative
0.04
Price Trends
0.03
Negative
0.04
Negative
0.03
Negative
Market Momentum
>-0.01
Positive
13.18
Positive
-29.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PKY, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 13.18 is Positive, neither overbought nor oversold. The STOCH value of -29.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PKY.
Opyl Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$569.74M | 33.84 | 21.61% | 1.77% | 6.95% | 10.77% | |
61 Neutral | AU$134.98M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$121.68M | -6.31 | -203.69% | ― | -1.53% | 28.29% | |
49 Neutral | AU$26.58M | -1.38 | -58.13% | ― | 2.08% | -195.31% | |
42 Neutral | AU$31.09M | -2.77 | -18.10% | ― | ― | ― | |
41 Neutral | AU$8.29M | -0.48 | -614.15% | ― | -46.09% | 70.70% |
* Healthcare Sector Average
AU:PKY
Opyl Ltd.
0.02
0.00
0.00%
AU:CGS
Cogstate Ltd
3.39
0.98
40.78%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.15
-0.06
-27.50%
AU:BMT
Beamtree Holdings Ltd
0.09
-0.12
-57.14%
AU:AHE
MedAdvisor Limited
0.02
-0.03
-64.29%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
Opyl Ltd. Corporate Events
PathKey.AI Sets November AGM to Review 2026 Results and Executive Pay
Oct 2, 2026
PathKey.AI Ltd has convened its Annual General Meeting for 5 November 2026 in West Perth, where shareholders will review the company’s Annual Report for the year ended 30 June 2026, including financial statements, directors’ report and...
Pathkey.AI sets AGM date and deadline for director nominations
Sep 15, 2026
Pathkey.AI Ltd has scheduled its Annual General Meeting for 29 October 2026, where the election and re-election of directors will be on the agenda. The company has set 23 September 2026 as the deadline for receiving director nominations at its reg...
Pathkey.AI Forms Advisory Board to Drive Chipforge Commercialisation
Sep 10, 2026
Pathkey.AI Ltd has established an Advisory Board to accelerate the build-out and commercialisation of its recently acquired Chipforge AI-native semiconductor design platform. The inaugural appointment is Associate Professor Anupam Chattopadhyay of...
Pathkey.AI Issues New ASX-Listed Shares Under Disclosure Exemption
Sep 4, 2026
Pathkey.AI Ltd has issued 1,150,000 fully paid ordinary shares on 4 September 2026, identified on the ASX under code PKY, without a prospectus or other disclosure document under the capital-raising provisions of the Corporations Act.The board-appr...
PathKey.AI Seeks ASX Quotation for New Share Issue
Sep 4, 2026
PathKey.AI has applied to the ASX for quotation of 1,150,000 new ordinary fully paid shares under its existing PKY code. The securities, issued on 4 September 2026, arise from the exercise or conversion of options or other convertible instruments,...
Pathkey.AI details corporate structure and ASX listing information
Aug 31, 2026
Pathkey.AI Ltd has outlined its key corporate directory details, including its board composition, company secretary, and principal place of business in Sydney. The release also confirms its share registry, auditor, and ASX listing information, rei...
Pathkey.AI Widens Loss Despite Revenue Surge and Chipforge Acquisition
Aug 31, 2026
Pathkey.AI Ltd reported a 71.4% rise in revenue to $47,632 for the year ended 30 June 2026, but its net loss widened 152.3% to $3.65 million, with no dividends declared. The group’s net tangible assets per share improved to 0.26 cents from n...
Pathkey.AI issues new shares under streamlined disclosure provisions
Aug 20, 2026
Pathkey.AI Ltd has issued 7,452,380 fully paid ordinary shares on 20 August 2026, and has notified the market that these securities were issued without a prospectus or other disclosure document under the relevant capital-raising provisions of the ...
Pathkey.ai Seeks ASX Quotation for Over 5.4 Million New Shares
Aug 20, 2026
Pathkey.ai Ltd, an artificial intelligence-focused technology company listed on the ASX under the code PKY, provides investors with exposure to the growth of AI and data-driven solutions. Its ordinary fully paid shares are the primary vehicle thro...
Pathkey.AI Seeks ASX Quotation for 2 Million New Shares
Aug 20, 2026
Pathkey.AI Ltd has applied for the quotation of 2,000,000 ordinary fully paid shares on the Australian Securities Exchange, with the securities issued on August 20, 2026. The move expands the company’s listed capital base, potentially enhanc...
Pathkey.ai Issues 21.8 Million Unquoted Options
Aug 20, 2026
Pathkey.ai Ltd has notified the ASX of the issue of 21,800,000 unquoted options, all classified under the PKYAA security code and expiring on various dates at various exercise prices. The options, which are not intended to be quoted, form part of ...
PATHKEY.AI Issues 10 Million Unquoted Options to Support Capital Strategy
Aug 20, 2026
LTD PATHKEY.AI has notified the market of the issuance of 10,000,000 unquoted options, each exercisable at $0.05 and expiring on 17 December 2027. The options, recorded under ASX security code PKYAE, form part of previously announced transactions ...
Pathkey.AI Issues 100 Million New Shares in ASX-Compliant Placement
Aug 20, 2026
Pathkey.AI Ltd has issued 100,000,000 fully paid ordinary shares on 20 August 2026, notifying the market that this capital raising was conducted without a prospectus or other disclosure document under the Corporations Act. The company affirms it i...
Pathkey.ai Seeks ASX Quotation for 100 Million Ordinary Shares
Aug 20, 2026
Pathkey.ai Ltd has lodged an application with the ASX for the quotation of 100,000,000 ordinary fully paid shares under the code PKY, with an issue date of 20 August 2026. The move formalises the company’s capital structure on the exchange a...
Pathkey.AI Director Damon Rasheed Lifts Indirect Shareholding
Aug 18, 2026
Non-executive director Damon Rasheed has increased his indirect shareholding in Pathkey.AI Ltd through an on-market purchase. Rasheed, via controlled entity DR Globalex Pty Ltd, acquired 200,000 ordinary shares for $7,600, adding to his existing m...
PathKey.ai Plans Issue of 40 Million Performance Rights on ASX
Aug 12, 2026
PathKey.ai Ltd has notified the ASX of a proposed issue of up to 40 million performance rights under its PKYAAA class. The securities are to be issued via a placement or other structured issuance, with a proposed issue date of 20 August 2026.The m...
PathKey.ai Plans Large ASX Share Placement to Raise Capital
Aug 12, 2026
PathKey.ai Ltd has notified the ASX of a proposed placement of up to 100,000,000 ordinary fully paid shares, with a planned issue date of 20 August 2026. The company has applied for quotation of the new securities in accordance with ASX listing ru...
Pathkey.AI Brings In Former Altium Chair Sam Weiss and Secures $2.8m Placement
Aug 12, 2026
Pathkey.AI has appointed former Altium Limited chairman Sam Weiss as strategic advisor to its CEO and Chipforge team, leveraging his experience in scaling design software into a global leader and his insight into the convergence of electronic desi...
Chipforge Wins First Commercial Contract Ahead of AI Chip Platform Launch
Aug 11, 2026
Pathkey.AI’s chip design subsidiary Chipforge has secured its first commercial customer contract ahead of the general release of its AI-native Chipforge platform, marking the company’s initial revenue from the technology. The deal is w...
Pathkey.AI Shares Halted Ahead of Capital Raising Announcement
Aug 10, 2026
Pathkey.AI Ltd has requested and received a trading halt on its securities from the ASX, effective 10 August 2026, while it prepares a market announcement. The halt will remain in place until either the release of the announcement or the resumptio...
Pathkey.AI accelerates AI chip design with Chipforge acquisition and expands TrialKey revenues
Jul 31, 2026
Pathkey.AI has completed the acquisition of Singapore-based Chipforge, integrating its AI-powered platform that turns high-level design intent into verified hardware code, significantly compressing traditional chip development cycles and supportin...
Pathkey.AI issues 38.7 million new shares under compliance notice
Jul 10, 2026
Pathkey.AI Ltd has issued 38,654,492 fully paid ordinary shares on 10 July 2026, identified on the ASX under the code PKY. The issuance was conducted without a formal disclosure document under the capital raising provisions of the Corporations Act...
Pathkey.ai Plans New Placement of Options and Shares on ASX
Jul 10, 2026
Pathkey.ai Ltd has notified the ASX of a proposed securities issue comprising up to 30 million options and 2 million ordinary fully paid shares. The instruments are to be issued by way of a placement or similar structure, with a proposed issue dat...
Pathkey.ai Seeks ASX Quotation for 38.7 Million New Shares
Jul 10, 2026
Pathkey.ai Ltd, an ASX-listed technology company trading under the code PKY, focuses on artificial intelligence solutions and digital platforms targeting enterprise and data-intensive applications. Its operations reflect the broader growth trend i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.